Dyne Therapeutics, Inc. cotiza a 15.30 USD y tiene una capitalización bursátil de $2.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy;…
| Periodo | 2026-11 | 2026-07 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.08 | $-0.73 | $-0.73 |
| Estimado | $-0.89 | $-0.75 | $-0.78 | $-0.76 |
| Sorpresa | — | -44.0% | +6.4% | +3.9% |
| Métrica | DYN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -45.9% | -40.4% | -5.5% |
| ROA | -37.6% | -32.0% | -5.6% |
| Current Ratio | 22.25 | 2.84 | +19.41 |
| Debt / Equity | 0.15 | 0.28 | -0.13 |